Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2023-01-13

Clinical Trial Update: Long Term Safety of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus [Phase 3]

View source ↗

Summary

A long-term safety update for anifrolumab in adults with active systemic lupus erythematosus (Phase 3) has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Anifrolumab (anifrolumab)

Snippet

Sponsor: AstraZeneca | Conditions: Active Systemic Lupus Erythematosus | Phase 3 | Status: COMPLETED | Results posted: 2023-01-13